CStone Pharmaceuticals (2616) Fundamentals 2026 — Revenue Analysis | SniperIQ
CStone Pharmaceuticals (2616) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$7.6B, trading at HK$4.74 on the HKSE. This SniperIQ fundamentals page covers CStone Pharmaceuticals's valuation, profitability (net margin -123.3%), revenue (¥270M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CStone Pharmaceuticals's market cap?
CStone Pharmaceuticals (2616) has a market capitalization of approximately HK$7.6B, trading at HK$4.74 on the HKSE. Market cap moves with the live share price.
What is CStone Pharmaceuticals's P/E ratio?
CStone Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CStone Pharmaceuticals?
CStone Pharmaceuticals runs a net profit margin of -123.3%, a gross margin of 39.9%, and an operating margin of -120.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CStone Pharmaceuticals generate?
CStone Pharmaceuticals reported revenue of ¥270M for fiscal year 2025, with net income of -¥437M and earnings per share (EPS) of -0.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does CStone Pharmaceuticals pay a dividend?
CStone Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CStone Pharmaceuticals financially healthy?
CStone Pharmaceuticals carries a debt-to-equity ratio of 0.57x and a current ratio of 2.18x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CStone Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CStone Pharmaceuticals (2616) the key facts are: market cap HK$7.6B, revenue ¥270M, 52-week range 4.01-13.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track CStone Pharmaceuticals's full fundamentals live
Get CStone Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.